Study summary
A standard narcolepsy drug also helped many people lose weight
26%of people lost 5% or more of their body weight
What was tested
A look back at weight changes in two phase 3 trials of low-sodium oxybate, an existing narcolepsy and idiopathic hypersomnia treatment, in people who were overweight or obese.
What they found
- 26% of people new to oxybate treatment lost at least 5% of their body weight.
- Weight loss was smaller in people already taking oxybate before switching.
What it means
A secondary benefit worth discussing, alongside oveporexton, for narcolepsy patients who are overweight.
Last reviewed 2026-11-14 by the Find a Trial editorial team.
Information on this page is for educational purposes and is not medical advice.
Always consult qualified healthcare professionals about clinical trial participation.